Not available
Quote | Astellas Pharma Inc (OTCMKTS:ALPMF)
Last: | $9.8414 |
---|---|
Change Percent: | -1.05% |
Open: | $9.6 |
Close: | $9.8414 |
High: | $9.8414 |
Low: | $9.6 |
Volume: | 22,820 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Astellas Pharma Inc (OTCMKTS:ALPMF)
2024-04-25 03:54:46 ET More on Astellas Pharma: Pfizer, Astellas first-line bladder cancer therapy accepted for review in China Astellas collaborates with Mass General Brigham for translational medicine Historical earnings data for Astellas Pharma Read the ...
2024-04-24 11:12:04 ET Major earnings expected before the bell on Thursday include: Bristol-Myers Squibb ( BMY ) Caterpillar ( CAT ) Comcast ( CMCSA ) Altria Group ( MO ) Merck & Co ( MRK ) Read the full article on Seeking Alpha Fo...
Message Board Posts | Astellas Pharma Inc (OTCMKTS:ALPMF)
Subject | By | Source | When |
---|---|---|---|
Astellas' Main Products: | scoobey-do | investorshub | 01/02/2021 7:43:55 PM |
Astellas Aspiration: | scoobey-do | investorshub | 01/02/2021 7:37:09 PM |
Astellas Innovation Management ($AIM) sounds like a partnership | SPORT19 | investorshub | 01/02/2021 5:25:04 PM |
One week ago ProtoKinetix $CEO Clarence Smith posted | SPORT19 | investorshub | 01/02/2021 5:24:42 PM |
Astellas has undergone a MASSIVE expansion of its | SPORT19 | investorshub | 01/02/2021 5:24:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 unde...